医药圈被美国昔日“宇宙大药厂”辉瑞以12.5亿美元首付款及48亿美元的里程碑付款引进三生制药PD-1/VEGF双抗(SSGJ-707)的消息刷屏。三生制药业受此消息影响,市值(股价)涨幅超30%,企业市值逼近500亿港元。然而,这起交易的买方辉瑞其势头早已不如往日,犹如英雄迟暮。根据公开消息:辉瑞当前市值约为1307.63亿美元,在全球药企市值排名中位列第11名,略低于第10名的吉利德科学(约...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.